The National Institute for Health and Care Excellence (NICE) has issued positive final draft guidance recommending Dupixent (dupilumab) as a treatment option for severe, uncontrolled chronic obstructive pulmonary disease (COPD) in England. This decision, announced on Tuesday, paves the way for a significant new therapeutic avenue for patients living with this debilitating respiratory condition.
Dupixent, developed by Sanofi and Regeneron, is recommended for adults who have severe COPD with an eosinophilic phenotype, meaning they have elevated levels of a type of white blood cell called eosinophils. Crucially, this treatment is intended for patients whose condition remains uncontrolled despite receiving maximal standard inhaled therapy, including triple therapy with inhaled corticosteroids, long-acting beta-agonists, and long-acting muscarinic antagonists.
This landmark recommendation marks the first time a biologic treatment has been specifically approved for COPD in England. Biologics are a class of drugs derived from living organisms, offering targeted action against specific disease pathways. For COPD, which affects millions of people across the UK, the introduction of such a targeted therapy represents a substantial advancement in treatment options, particularly for those with a severe form of the disease that significantly impacts their daily lives.
The positive guidance from NICE follows a commercial agreement between NHS England and the manufacturers, Sanofi and Regeneron, ensuring the treatment can be made available at a cost-effective price. This agreement is vital for the integration of new, often high-cost, medicines into the NHS framework, balancing patient access with financial sustainability. It is estimated that approximately 100,000 people in England could be eligible for this new treatment, offering hope for improved respiratory function and reduced exacerbations.
COPD is a progressive lung disease that causes airflow obstruction, leading to symptoms such as breathlessness, chronic cough, and frequent chest infections. Severe COPD can lead to frequent hospital admissions and a significant reduction in quality of life. The availability of Dupixent is expected to help reduce the frequency of exacerbations, which are periods of acute worsening of respiratory symptoms, thereby potentially decreasing hospitalisations and improving overall patient outcomes.
While this guidance applies to England, similar appraisal processes would typically follow in Wales and Northern Ireland, often aligning with NICE recommendations. Scotland has its own appraisal body, the Scottish Medicines Consortium (SMC), which would conduct an independent assessment.